论文部分内容阅读
目的观察洛铂(lobaplatin,LBP)或顺铂(cisplatin,DDP)分别联合依托泊苷(etoposide,VP-16)治疗广泛期小细胞肺癌(small cell lung cancer,SCLC)的近期疗效、不良反应和住院情况。方法 46例广泛期SCLC分为DDP联合VP-16的EP组23例,LBP联合VP-16的EL组23例。21d为1周期,连用2个周期评价近期疗效、毒性反应及住院情况。结果 EL组和EP组比较,客观有效率、住院时间、白细胞下降率及血小板下降率,均无显著性差异。两组化疗后肺癌肿瘤标志物中神经元特异性烯醇化酶(NSE)均明显减低,但癌胚抗原(CEA)和细胞角蛋白19片段(CYFRA21-1)无明显减低,两组之间无显著性差异。EL组消化道反应率明显减低,但诊疗费用明显增加。结论 EL和EP同样为广泛期SCLC安全有效的化疗方案,EL组消化道反应明显减少,但医疗费用明显增加。
Objective To observe the short-term curative effect and side effects of lobaplatin (LBP) or cisplatin (DDP) combined with etoposide (VP-16) in the treatment of extensive-stage small cell lung cancer Hospitalization. Methods Totally 46 cases of extensive SCLC were divided into EP group of DDP and VP-16, 23 cases of LB group and EL-VP-16 group. 21d for 1 cycle, even with 2 cycles to evaluate the recent efficacy, toxicity and hospitalization. Results There was no significant difference in objective efficiency, length of hospital stay, leukopenia and platelet decline between the EL and EP groups. The NSE of lung cancer tumor markers were significantly decreased in both groups, but CEA and CYFRA21-1 were not significantly reduced in both groups, with no significant difference between the two groups Significant difference. EL group gastrointestinal reaction rate was significantly reduced, but the cost of treatment increased significantly. Conclusions Both EL and EP are safe and effective chemotherapy regimens in a wide range of SCLC. The gastrointestinal reactions of EL patients are significantly reduced, but the medical costs are obviously increased.